LIFERIVER reported a net loss of 128 million yuan for the fiscal year 2024
I'm LongbridgeAI, I can summarize articles.LIFERIVER released its 2024 annual performance preliminary report, achieving total operating revenue of 183 million yuan during the reporting period, a year-on-year decrease of 33.15%, with a net loss attributable to the parent company's owners of 128 million yuan. The company continues to strengthen investment in product research and development, expand new product lines, enhance marketing in the fields of respiratory diseases, gynecological tumors, and liver diseases, actively explore international markets, and implement cost reduction and efficiency enhancement measures to improve operational management efficiency and profitability
According to the Zhitong Finance APP, LIFERIVER (688317.SH) released its performance preliminary report for the year 2024. During the reporting period, the company achieved total operating revenue of 183 million yuan, a year-on-year decrease of 33.15%, with a net loss attributable to the parent company of 128 million yuan.
During the reporting period, the company continued to strengthen investment in product research and development, constantly expanding new product lines and enriching its product matrix; it enhanced marketing and promotion in the fields of respiratory diseases, gynecological tumors, and liver diseases, actively exploring international markets; and it continued to implement measures to reduce costs and increase efficiency to improve operational management efficiency, enhance the company's profitability, and achieve sustainable development